NEW YORK (GenomeWeb News) – Response Biomedical has completed a 20-for-one share consolidation, the Vancouver, British Columbia-based firm said yesterday after the close of the market.

The diagnostics firm said that it expects its post-consolidation common shares will begin trading on the Toronto Stock Exchange and the OTC Bulletin Board in the US on Sept. 26. It announced the share consolidation last month.

The shares were trading at $.08 on the OTC Bulletin Board, with no shares trading hands, early Tuesday afternoon.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.